CONMED Corporation Stock News

HSIC vs. CNMD: Which Stock Is the Better Value Option?

New York, USA, March 01, 2022 (GLOBE NEWSWIRE) -- The Global Powered Surgical Instruments Market Is Expected To Exhibit Strong Growth With a CAGR of 4.26% In The Coming Years , Assess DelveInsight As per DelveInsight analysis, the Powered Surgical Instruments market is growing positively due to the factors such as an increase in geriatric population, having a high prevalence of bone disorders and ophthalmic conditions, and along with the increasing incidence of brain cancers as well increase in the number of trauma cases, and a parallel growth in product innovation. DelveInsight''s Powered Surgical Instruments Market Insights report provides the current and forecast Powered Surgical Instruments market, upcoming device innovation, individual leading Powered Surgical Instruments device companies market shares, challenges, drivers, barriers, and market trends and key Powered Surgical Instruments companies in the market. Key Takeaways from the Global Powered Surgical Instruments Market According to DelveInsight analysis, North America is expected to dominate the overall Powered Surgical Instruments market during the forecast period.

New York, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Minimally Invasive Surgical Systems Market: Focus on Product Type, Application, End Users, 25 Countries'' Data, Patent Scenario, and Competitive Landscape - Analysis and Forecast, 2021-2031" - https://www.reportlinker.com/p06135349/?utm_source=GNW Market Segmentation • Product - Conventional Technologies (Endoscopes and Endoscopic Systems, Video and Visualization Systems, Capsule Endoscopy, Instruments and Accessories, Others), Surgical Robotics (Robotic Systems, Instruments and Accessories, Services) • Application - General Surgery, Urology Surgery, Gynecology Surgery, Orthopedic Surgery, Cardiovascular Surgery, Neurosurgery, Others • End User - Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics • Region - North America, Europe, Asia-Pacific, Latin America, Middle East and Africa Regional Segmentation • North America - U.S., Canada • Europe - Germany, France, Spain, U.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Endoscopy Equipment Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow. Northbrook, IL -- ( SBWIRE ) -- 02/24/2022 -- This report aims to provide detailed insights into the global endoscopy equipment market . It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market. Expected Revenue Growth: The global endoscopy equipment market is projected to reach USD 39.3 billion by 2026 from USD 27.3 billion in 2021, at a CAGR of 7.5%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689 Key Factors Driving Market Growth: The key factors driving the growth of endoscopy equipment market include favorable government initiatives, rising number of hospitals and growing hospital investments in endoscopy facilities, technological advancements, and rising prevalence of diseases that require endoscopy.

HSIC vs. CNMD: Which Stock Is the Better Value Option?

CONMED Corporation (NYSE: CNMD ) reported Q4 FY21 adjusted EPS of $1.07 , compared to $0.84 a year ago, and better than the consensus of $1.06. Sales for the quarter rose 8.4% Y/Y to $273.97 million, missing the consensus of $278.76 … Full story available on Benzinga.com

CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.

CONMED Corporation (CNMD) CEO Curt Hartman On Q4 2021 Results - Earnings Call Transcript

We think that Stryker Corporation currently is a better bet compared to Conmed Corp. CNMD stock trades at 4x trailing revenues, lower than that of SYK, whose P/S multiple stands at 6.1x. Does this gap

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed

PDCO vs. CNMD: Which Stock Is the Better Value Option?

CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Earnings and Valuation This table compares CONMED and ViewRays top-line revenue, earnings per share and valuation. Gross Revenue [] The post Contrasting CONMED (NYSE:CNMD) and ViewRay (NASDAQ:VRAY) appeared first on ETF Daily News .

Los Angeles, United State, ,- This research study is one of the most detailed and accurate ones that solely focus on the global Gastrointestinal Bleeding Treatment market. It sheds light on critical factors that impact the growth of the global